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Abstract: A sensitive, selective, precise and stability-indicating, new high-perfor-
mance liquid chromatographic method for the analysis of carvedilol both as a bulk
drug and in formulations was developed and validated. As the method could effec-
tively separate the drug from its degradation products, it can be employed as a stabil-
ity-indicating one. The method was validated for linearity, selectivity, precision, ro-
bustness, LOD, LOQ and accuracy. The chromatographic separation was achieved
on a Chromolit RP 8e, 100  4.6 mm, analytical column. The mobile phase consisted
of a mixture of acetonitrile and water (45:55, V/V) (pH 2.5), pH adjusted with for-
mic acid. The absorbance was monitored with a UV detector at 280 nm and the tem-
perature of the analyses was 40 °C. The flow rate was 0.5 mL/min. The linearity (r 
0.999), reproducibility (0.68–1.27 %) and recovery (99.71–101.58) were found to
be satisfactory. This method enables the simultaneous determination of carvedilol
and its degradation products, as well as stability.
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INTRODUCTION
Carvedilol is a non-selective beta-receptor blocking agent and a vasodilatation
drug with antioxidant activity.1 It has been confirmed that carvedilol shows a far
greater antioxidant activity than other commonly used beta-blockers.2,3 Carvedilol
is used in the treatment of mild to moderate hypertension and angina pectoris,4,5
congestive heart failure (CHF)6 and is often used in combination with other drugs.
Chemically it is named (±)-1-(carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)et-
hyl)amino)-2-propanol. Carvedilol is a racemic compound.
Stereoselectivity of the carvedilol enantiomers was established. The effects of
the levorotatory S(-)-enantiomer are vasodilatation and beta blocking. The R(+)-en-
antiomer is a pure vasodilatation agent.
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Carvedilol is officially recognized in the European Pharmacopoeia in the pure
form, but not in dosage forms. Different analytical methods have been developed for
the determination of carvedilol, its metabolities and enantiomers including liquid
chromatography,7–12 liquid chromatography-mass spectrometry-mass spectrometry
(HPLC/MS/MS),13 and electrophoresis.14–16 There are also some published reports
of carvedilol determination by spectrofluorimetry17 and differential pulse voltam-
metry.18 However, there are neither published reports of the quantification assay of
carvedilol in the presence of its impurities nor stability studies of this drug.
Therefore, the aim of this work was to determine the optimal conditions for si-
multaneous separation and determination of carvedilol and its potential impurities
in pharmaceutical dosage forms, as well as to monitor the photochemical stability
of carvedilol. A new stability-indicating RP-HPLC method was validated for the
simultaneous determination of 4-hydroxycarbazole, impurity C and carvedilol.
Impurity C, chemically named (2RS)-1-benzyl-[2-(2-methoxyphenoxy)ethylami-
no]-3-(9H-carbazol-4-yloxy)propan-2-ol is a Pharmacopoeia and 4-hydroxycar-
bazole a non-Pharmacopoeia impurity.
The chemical structures of carvedilol and its degradation product 4-hydroxy-
carbazole are given in Fig. 1. As can be seen, 4-hydroxycarbazole is used for the
synthesis of carvedilol, hence it is questionable whether it is a synthesis impurity.
This topic could be the subject of some future investigations.
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Fig. 1. Synthesis of carvedilol.
EXPERIMENTAL
Chemicals and reagents
A standard of carvedilol was supplied by NOSCH, Labs Private Limited, India. A standard of
4-hydroxycarbazole was obtained from Sigma-Aldrich (Gmbh, Germany). Reagent-grade acetic acid
and formic acid were provided by Lachema (Brno, Czech Republic). HPLC-grade water, acetonitrile
and methanol were supplied by Merck, Darmstadt, Germany. Impurity C was also supplied by Merck.
Instrumentation and chromatographic conditions
The chromatographic analyses were performed with a liquid chromatograph HP HPLC 1100, a
Rheodyne 7725i injector valve with a 20 L loop, and HP model G13141A UV-VIS variable wave-
length detector.
The Analytiical column was Chromolit RP 8e, 100  4.6 mm. The mobile phase consisted of
acetonitrile, water (45:55, V/V) (pH 2.5), pH adjusted with formic acid. Isocratic elution was per-
formed at a flow rate of 0.5 mL/min. The UV-detection was performed at 280 nm. Injections were
carried out using a 20 L loop. All separations were carried out at a temperature of 40 °C.
Preparation of samples and standard working solutions
Stock solutions
The stock solution of 4-hydroxycarbazole had a concentration of 0.1 mg/mL; the stock solu-
tion of impurity C had a concentration of 0.2 mg/mL; the stock solution of carvedilol had a concen-
tration of 0.1 mg/mL.
All the samples and standard working solutions were prepared in the mobile phase in the re-
quired concentrations and filtered through a 0.45 m membrane filter.
Calibration solutions
A series of 5 standard solutions of 4-hydroxycarbazole were prepared by dilution of the stock solu-
tion to obtain a concentration range of 0.5–1.1 g/mL. Calibration solutions for carvedilol were pre-
pared by diluting the stock solution to obtain concentrations of 16–24 g/mL. Calibration solutions for
impurity C were prepared by diluting the stock solution to obtain concentrations of 0.96–1.44 g/mL.
Samples preparation
KarvileksR tablets were used for the examinations. One tablet contains 12.5 mg active sub-
stance for carvedilol and other ingredients. The average mass of the tablets is 125 mg.
Sample solutions were prepared by first making stock solutions. Twenty tablets were weighed and
finely powdered. Then the quantity of the powder containing 12.5 mg of carvedilol for assay (solu-
tion 1) and 50 mg for related substances (solution 2) were weighed in a 50 mL volumetric flask and
about 30 mL of mobile phase was added to each one. Both flasks were sonicated in an ultrasonic bath
for 30 min. The volume was made up to the mark with mobile phase, mixed well and filtered. For as-
say, 2.0 mL of solution 1 was diluted to 25.0 mL with mobile phase. The concentrations of carvedilol
were 0.02 mg/mL for assay and 1 mg/mL for related substances.
For monitoring the photochemical stability, carvedilol powder (1 g), distributed in a thin layer (<1
mm) on a small Petri dish, was exposed to continuous daylight for 100 days at room temperature (25 °C).
The other sample was kept in a dark place to compare degradation with and without daylight exposition.
The quantity of the powder containing 25 mg of carvedilol was dissolved in 25 ml of mobile phase and
sonicated in an ultrasonic bath for 15 min (the concentration of the sample preparation were 1 mg/mL).
Standard preparation
The working standard solution for related substances contained carvedilol in a concentration
of 1 mg/mL, 4-hydroxycarbazole in a concentration of 0.001 mg/mL and impurity C in a concentra-
tion of 0.002 mg/mL. The working standard solution for the test assay contained carvedilol in a con-
centration of 0.02 mg/mL.
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RESULTS AND DISCUSSION
Optimum conditions for the chromatographic procedure
The combined effects of pH and mobile phase composition of the reverse-phase
liquid chromatographic behavior of carvedilol and 4-hydroxycarbazole were studied.
The effects of these factors were examined in the range of conditions where they pro-
vided acceptable retention, resolution, tailing factor and number of theoretical plates.
pH between 2.1–2.7 has no significant influence on the results. The optimum pH was
2.5 because at pH values higher than 2.7, a somewhat larger peak tailing and inferior
resolution resulted. In comparison with other commonly used -blockers (pK
a
around
9.5), carvedilol has a pKa value of 7.97. The origin of the discrepancy in the pKa values
between carvedilol and other -blockers is attributed primarily to the inductive effect
of the -O-atom, which lowers the basicity of the amino group.
19 Different ratios of
acetonitrile and water, between 30:70 to 70:30 were investigated and the composition
of acetonitrile and water in mobile phase of 45:55 was found to be optimal, because
higher concentrations of water disturbed the separation and resolution. If methanol
was used instead of acetonitrile, the separation of carvedilol and the impurities was
also with unsatisfactory resolution.
As is shown in Fig. 2, the retention times of carvedilol and its related sub-
stances were 3.4 min, 5.2 min, and 6.0 min, respectively. The separation of
carvedilol from 4-hydroxycarbazole and impurity C is shown in Fig. 2.
Quantitative determination
The HPLC method was tested for selectivity, linearity, precision and accuracy.
The response (peak area) was proportional to concentration over the tested ranges,
i.e., between 16–24 g/mL for carvedilol, between 0.5–1.5 g/mL for 4-hydroxy-
carbazole and between 0.96–1.44 g/mL for impurity C. The parameters of cali-
bration curve: slope (a), intercept (b), correlation coefficient (R) are given in the
following regression equations:
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Fig. 2. Chromatogram showing the separation of carvedilol, 4-hydroxycarbazole and impurity C.
y = 70531x + 13.708 for carvedilol R2 = 0.9992
y = 131040x + 4.230 for 4-hydroxycarbazole R2 = 0.9995
y = 93442x – 5.424 for impurity C R2 = 0.9993
The selectivity of HPLC method was confirmed by injecting blank samples,
placebos and standard solutions. No other peaks corresponding to the retention
times of carvedilol and its impurities were noted, indicating that interfering sub-
stances were not present.
The precision of analytical system was investigated by using standard solu-
tions. Six consecutive replicate injections of each sample gave relative standard
deviations of 0.68 % for carvedilol, 1.02 % for impurity C and 0.87 % for
4-hydroxycarbazole.
The accuracy of the method was provided by the determination of 4-hydroxy-
carbazole and impurity C in the presence of carvedilol. A solution (c = 1 mg/mL)
containing carvedilol with no detectable amount of impurities was spiked with
aliquots of the impurities at adequate concentrations. The limit of detection (LOD)
was calculated to be three times the standard deviation of the noise ratio from the
analysis of each compound.
The limit of quantification (LOQ) was measured as the lowest amount of
analyte that can be reproducibly quantified above the baseline noise, for which du-
plicate injection resulted in a RSD  2 %. The validation parameters of the HPLC
method are shown in Table I.
TABLE I. Validation parameters of the HPLC method
Sample RSD/% Recovery/% LOD/g mL-1 LOQ/g mL-1
Carvedilol 0.68 101.58 0.007 0.026
Impurity C 1.02 100.43 0.042 0.061
4-Hydroxycarbazole 0.87 99.71 0.036 0.048
Stability study
The purpose of the stability testing was to investigate how the quality of a drug
product changes with time under the influence of environmental factors. Since
daylight-induced degradation of the drug may have a negative impact on the qual-
ity, safety and effectiveness of pharmacotherapy, research focused on this point is
definitely reasonable.
The RP-HPLC method for monitoring of the photochemical stability of
carvedilol is presented here. Carvedilol was exposed to daylight. The presence of
degradation products was observed. The percentage (%) of the degradation prod-
ucts were observed every 20 days for 100 days. The results are given in Table II.
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TABLE II. Degradation products (%)
Degradation products/time of exposure 0 day 20 day 40 day 60 day 80 day 100 day
4-Hydroxycarbazole 0.01 0.012 0.028 0.044 0.065 0.081
Impurity C – – – – – –
Unknown impurity – 0.016 0.038 0.062 0.087 0.11
4-Hydroxycarbazole was detected in the exposed sample by RP-HPLC analysis.
The impurity C– (2RS)-1-(2-(2-methoxyphenoxy)ethyl)amino)-3-(9H-carbazol-4-ylo-
xy)propan-2-ol was not detected after this period under the described conditions. The
presence of 4-hydroxycarbazole in the exposed sample of carvedilol was confirmed by
agreement of tR value (HPLC) of the standard solution of 4-hydroxycarbazole and tR
value of the solution of carvedilol after exposition to daylight. This agreement was also
confirmed by application of an additional amount of standard solution (4-hydroxy-
carbazole) to the sample and a significant increase of the peak area was determined.
Fig. 3 shows the chromatogram of a sample after 100 days of exposition to daylight. In
addition, the presence of another unkown degradation product is visible on this
chromatogram with a retention time of 7.68 min.
CONCLUSION
On the bases of the experimental results, the proposed method is suitable for the
simultaneous qualitative and quantitative determination of carvedilol and related sub-
stances in pharmaceutical formulations, as well as for use for stability testing.
The method provides great sensitivity, adequate linearity and repeatability. It
is also quicker and simpler for sample preparation than already offered procedures.
The chromolit column guarantees better peak shape, better resolution and lower
pressure during operation in comparison with previous methods.
It was shown that carvedilol is a relatively photostable compound. Carvedilol
can be exposed to daylight to obtain its decomposition products. As the main de-
composition product, 4-hydroxycarbazole was found by RP-HPLC. 4-Hydroxy-
carbazole was also determined in the sample of the raw material, hence it can be
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Fig. 3. Chromatogram of degraded carvedilol after a 100-day exposition to daylight.
supposed that it is a synthesis impurity. Impurity C was not found under the de-
scribed conditions. The chromatogram of the exposed sample of carvedilol shows
that some other impurity is formed. A further study is necessary for the identifica-
tion of this decomposition product.
I Z V O D
PRA]EWE FOTOHEMIJSKE STABILNOSTI KARVEDILOLA I WEGOVIH
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Karvedilol je neselektivni beta blokator sa vazodilatatornim i antioksida-
tivnim svojstvima. Primewuje se u terapiji hipertenzije, angine pektoris i konge-
stivne sr~ane insuficijencije. Razvijena je i validirana nova HPLC metoda za isto-
vremenu kvalitativnu i kvantitativnu analizu karvedilola i wegovih ne~isto}a kao
i za pra}ewe fotohemijske stabilnosti ovog jediwewa. Metoda je validirana na
linearnost, selektivnost, preciznost, robustnost, LOD, LOQ i ta~nost. Optimalni
uslovi postignuti su kori{}ewem hromatografske kolone Chromolit RP 8e, 100  4,6
mm. Mobilnu fazu predstavqa sme{a acetonitrila i vode u odnosu 45:55 pri pH 2,5.
Analiza se odvija na temperaturi od 40 °C pri protoku 0,5 ml/min a talasna du`ina UV
detektora iznosi 280 nm. Linearnost (r  0,999), reproduktivnost (0,68–1,27 %), i
rikaveri (99,71–101,58) pokazuju zadovoqavaju}e vrednosti. Hromatografska analiza
je pokazala da se kao glavni proizvod degradacije karvedilola javqa 4-hidroksi-
karbazol, dok ne~isto}a C nije prisutna pod ovim uslovima. Predlo`ena RP-HPLC
metoda je brza, precizna, ta~na, osetqiva, pouzdana i primenqiva za kvalitativnu i
kvantitativnu analizu KarvileksR tablete, kao i za pra}ewe stabilnosti ovog leka.
(Primqeno 24. oktobra 2005, revidirano 12. aprila 2006)
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